Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$12.37 - $13.89 $384,979 - $432,284
-31,122 Reduced 63.04%
18,245 $240,000
Q4 2022

Feb 01, 2023

SELL
$11.8 - $13.78 $502,337 - $586,628
-42,571 Reduced 46.3%
49,367 $643,000
Q3 2022

Nov 02, 2022

SELL
$11.61 - $15.22 $198,705 - $260,490
-17,115 Reduced 15.69%
91,938 $1.07 Million
Q2 2022

Aug 03, 2022

BUY
$14.32 - $19.88 $1.08 Million - $1.49 Million
75,194 Added 222.08%
109,053 $1.61 Million
Q1 2022

Apr 28, 2022

BUY
$15.39 - $20.25 $521,090 - $685,644
33,859 New
33,859 $659,000
Q4 2021

Feb 02, 2022

SELL
$15.91 - $18.72 $591,852 - $696,384
-37,200 Closed
0 $0
Q4 2020

Mar 12, 2021

SELL
$9.33 - $12.48 $55,980 - $74,880
-6,000 Reduced 13.89%
37,200 $451,000
Q3 2020

Oct 29, 2020

BUY
$10.33 - $14.49 $446,256 - $625,968
43,200 New
43,200 $436,000
Q3 2019

Nov 14, 2019

SELL
$10.05 - $14.55 $1.03 Million - $1.5 Million
-102,833 Closed
0 $0
Q2 2019

Aug 01, 2019

BUY
$13.1 - $14.95 $398,240 - $454,480
30,400 Added 41.97%
102,833 $1.46 Million
Q1 2019

May 10, 2019

BUY
$13.69 - $20.06 $104,044 - $152,456
7,600 Added 11.72%
72,433 $1.05 Million
Q4 2018

Feb 12, 2019

SELL
$13.96 - $18.26 $106,096 - $138,776
-7,600 Reduced 10.49%
64,833 $1.1 Million
Q3 2018

Nov 09, 2018

BUY
$13.63 - $15.7 $24,983 - $28,778
1,833 Added 2.6%
72,433 $0
Q2 2018

Aug 14, 2018

BUY
$13.44 - $17.59 $60,480 - $79,155
4,500 Added 6.81%
70,600 $971,000
Q1 2018

May 03, 2018

BUY
$13.8 - $16.99 $125,580 - $154,609
9,100 Added 15.96%
66,100 $1.11 Million
Q3 2017

Nov 06, 2017

BUY
$12.06 - $14.12 $687,420 - $804,840
57,000
57,000 $720,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.24B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.